1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Доклад рабочей группы GOLD (Global Initiative for Chronic Obstructive Lung Disease) – пересмотр 2006. Под ред. А.Г.Чучалина.
2. Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Пульмонология. 2001; 1: 65–72.
3. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии β2-адреностимуляторов. Рус. мед. журн. 2001; 9 (21; 140): 930–3.
4. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993.
5. Anthonisen NR, Connett JE, Murray RP, for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–9.
6. Barnes PJ. Effects of β2-agonists and steroids on β2-adrenoreceptor. Eur Respir Rev 1998; 8 (55): 210–5.
7. Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–6.
8. Сazzola M et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114 (2): 411–5.
9. Calverley PMA, Anderson JA, Celli B et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356 (8): 775–89 & Online Supplements.
10. Dahl R, Greefhost LARM, Nowak D et al. Inhaled formoterol dry in cronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
11. Hall Ian P. Hall. β2-Adrenoreceptor agonists. In: Barnes P.J.: Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed., CopyrightC 2002 Academic Press.
12. Kallstrom BL, Sjoberg J, Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994; 113: 687–92.
13. Kottakis J, Wood R, Le Gros V, Della Cioppa G. Clinical efficacy with formoterol in the absence of a response to salmeterol: A review. Int J Clin Pract 2001; 55: 476–9.
14. Liggett SB. Polymorphisms of the β2-adrenergic receptor in asthma. Am J Respir Cri Care Med 1997; 156: 156–62.
15. Naline E, Zhang Y, Qian Y et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994; 7: 914–20.
16. Nials AT, Ball DI, Butchers PR et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35.
17. O'Connor BJ, Alkinan SL, Barnes PJ. Tolerance to the non-bronchodilatator effects of inhaled β2-agonists in asthma. N Engl J Med 1992.
18. Vestbo J. TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004; 24: 206–10.
19. van Noord JA, Smeets JJ, Raaijmakers JA et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.